CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03255018
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:26.978459+00:00
Published At: 2023-11-28T00:00:00+00:00
Record Updated At: 2023-11-28
Results Posted At: 2023-11-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Hodgkin Lymphoma", "Lymphoma", "Diffuse Large B-Cell Lymphoma", "Gray-zone Lymphoma", "Primary Central Nervous System Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-11-28"
protocolSection.identificationModule.nctId: "NCT03255018"
protocolSection.identificationModule.officialTitle: "Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-11-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.